<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04466618</url>
  </required_header>
  <id_info>
    <org_study_id>20-003993</org_study_id>
    <nct_id>NCT04466618</nct_id>
  </id_info>
  <brief_title>Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes</brief_title>
  <official_title>To Determine the Effect of Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adrian Vella</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GLP-1 is a hormone made by the body that promotes the production of insulin in response to
      eating. However, there is increasing evidence that this hormone might help support the body's
      ability to produce insulin when diabetes develops. The purpose of this study is to determine
      the effect of endogenous GLP-1 secretion on insulin secretion in people with and without type
      2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon Concentrations</measure>
    <time_frame>Average concentration over the 0-180minutes of study</time_frame>
    <description>Measured by immunoassay</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-9,39</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exendin-9,39 infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline + Intralipid/Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction of acute insulin resistance during Saline infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-9,39 + Intralipid/Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction of acute insulin resistance during Exendin-9,39 infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline infused during the study</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Exendin-9,39</intervention_name>
    <description>Exendin-9,39 infused during the study</description>
    <arm_group_label>Exendin-9,39</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Saline + Intralipid/Heparin</intervention_name>
    <description>Saline infused during acute insulin resistance</description>
    <arm_group_label>Saline + Intralipid/Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Exendin-9,39 + Intralipid/Heparin</intervention_name>
    <description>Exendin-9,39 infused during acute insulin resistance</description>
    <arm_group_label>Exendin-9,39 + Intralipid/Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria - non-diabetic subjects:

          -  Weight-stable, non-diabetic subjects

        Exclusion Criteria - non-diabetic subjects:

          -  Age &lt; 25 or &gt; 65 years (to avoid studying subjects who could have latent type 1
             diabetes, or the effects of age extremes in subjects with normal or impaired fasting
             glucose).

          -  HbA1c â‰¥ 6.5%

          -  Use of glucose-lowering agents.

          -  For female subjects: positive pregnancy test at the time of enrollment or study

          -  History of prior upper abdominal surgery such as adjustable gastric banding,
             pyloroplasty and vagotomy.

          -  Active systemic illness or malignancy.

          -  Symptomatic macrovascular or microvascular disease.

        Inclusion criteria - diabetic subjects:

          -  Weight-stable, diabetic subjects treated with diet and lifestyle alone or with
             metformin monotherapy

        Exclusion Criteria - diabetic subjects:

          -  Age &lt; 25 or &gt; 65 years (to avoid studying subjects who could have latent type 1
             diabetes, or the effects of age extremes in subjects with normal or impaired fasting
             glucose).

          -  Use of any glucose-lowering agent other than metformin.

          -  2 or more fasting glucose values &gt; 250mg/dl on medication or after medication
             withdrawal.

          -  Unwillingness or inability to withdraw medication for three weeks prior to, and for
             the duration of the study.

          -  For female subjects: positive pregnancy test at the time of enrollment or study

          -  History of prior upper abdominal surgery such as adjustable gastric banding,
             pyloroplasty and vagotomy.

          -  Active systemic illness or malignancy.

          -  Symptomatic macrovascular or microvascular disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Vella</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adrian Vella</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

